Key facts
- Mumac’s last known valuation is $3.4M (Apr 2025).
- It has raised $950K; the latest was Later Stage VC ($760K) in Apr 2025.
- Notable investors include The University of Manchester.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Mumac
- ·The full record, as it builds
Funding rounds
No funding rounds for Mumac are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mumac
Developer of medical instruments designed to fight against age-related macular degeneration. The company's instruments offer an early-alert digital screening process that uses dark adaptation to detect AMD, enabling patients to detect the disease in an early stage and thus prevent it from progressing if found.
- Sector
- Healthcare
- HQ
- Stockport, United Kingdom
- Founded
- 2016
- Employees
- 3
- Website
- mumacltd.com/
- Ownership
- Privately Held (backing)
Mumac doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mumac shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mumac in its N-PORT filings yet. We sweep new filings monthly.